Posts With Tag mantle cell lymphoma

AstraZeneca's Calquence receives EU approval for untreated MCL, offering new hope with improved survival rates. This report details clinical trial results and market implications.

Explore AstraZeneca's Calquence, the first BTK inhibitor recommended for 1st-line MCL in the EU, based on ECHO Phase III trial findings showcasing improved survival rates.

AstraZeneca's SEC filing highlights FDA approval of Calquence for mantle cell lymphoma, boosting patient outcomes and offering new hope. Key trial results show significant PFS improvement.